The binding of a potent synthetic androgen--methyltrienolone (R 1881)--to cytosol preparations of human prostatic cancer
- PMID: 84428
The binding of a potent synthetic androgen--methyltrienolone (R 1881)--to cytosol preparations of human prostatic cancer
Abstract
The binding of 3H-R 1881 to cytosol prepared from benign and malignant prostatic neoplasms has been investigated. We have demonstrated that high affinity binding of 3H-R 1881 is present in cytosol preparations of benign prostatic hyperplasia, in specimens of prostatic cancer obtained from patients prior to hormonal therapy and in carcinoma of the prostate metastatic to lymph nodes. In addition, high affinity binding was present in all specimens of prostatic cancer from patients who had objective evidence of progressive metastatic disease after an initial response to hormonal therapy. Until greater numbers of patients have been studied the significance of these findings can only be speculative. Because the binding of 3H-R 1881 may measure androgen and progesterone receptors future investigations must include careful steroid specificity studies. Finally, because steroidal hormones exert their major influence within the nucleus of target tissues the measurement of nuclear receptor content may provide a more accurate means to predict the hormonal responsiveness of prostatic cancer.
Similar articles
-
Characterization of the binding of a potent synthetic androgen, methyltrienolone, to human tissues.J Clin Invest. 1978 Jan;61(1):150-62. doi: 10.1172/JCI108913. J Clin Invest. 1978. PMID: 73547 Free PMC article.
-
A preliminary report on the measurement of cytosolic and nuclear prostatic tissue steroid receptors.Prog Clin Biol Res. 1979;33:209-21. Prog Clin Biol Res. 1979. PMID: 93750 No abstract available.
-
Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors.Cancer Res. 1983 Mar;43(3):1107-16. Cancer Res. 1983. PMID: 6186370
-
Androgen receptor assays in advanced prostatic cancer.Urol Clin North Am. 1984 May;11(2):311-7. Urol Clin North Am. 1984. PMID: 6375068 Review.
-
Human prostate steroid hormone receptor quantitation. Current methodology and possible utility as a clinical discriminant in carcinoma.Invest Urol. 1978 Nov;16(3):169-74. Invest Urol. 1978. PMID: 361632 Review. No abstract available.
Cited by
-
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.J Clin Invest. 2019 Jul 16;129(10):4245-4260. doi: 10.1172/JCI127613. J Clin Invest. 2019. PMID: 31310591 Free PMC article.